Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at the Rare Trials Summit 2025 in Boston in September.

 

The development of inclusion/exclusion criteria for clinical trial protocols can make or break drug development. Can we expand medical knowledge and discover new phenotypes and biomarkers for diseases – enabling precision targeting of the right patients for recruitment – by using data-driven machine learning methodologies?

Could we even find more rare disease patients than previously expected among the undiagnosed and the misdiagnosed?

All these – and more – in Volv Global SA CEO and founder Christopher Rudolf’s presentation at the 2025 Rare Trials Summit.

We’re grateful to the organisers of the Rare Trials Summit 2025 for the invitation to speak.

 

🟥 Rare Trials Summit 2025

• Rare Trials Summit is an annual conference bringing together key stakeholders in the rare disease clinical research community to solve the unique challenges of developing therapies for rare conditions and accelerate the development of new rare disease therapies from average 10-12 years to under 3 years. How do we speed up the development of life-changing therapies for rare diseases while keeping trials accessible, patient-centered, and scientifically sound? It is time to lean in to critical, hard discussions and collaboratively solve challenges facing rare disease research, therapeutics, and patients. Featuring experts from pharma, biotech, academia, CROs, regulators, and patient advocacy.
• September 9-10, 2025
• Sheraton Boston Hotel, Boston, MA, USA
• Website Rare Trials Summit 2025
• LinkedIn 2025 Rare Trials Summit – Boston Sep 9-10

 

🟥 Christopher’s talk

• “Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI”
• Tuesday, September 9, 01:15 PM – 01:45 PM
• Christopher Rudolf is a seasoned technology entrepreneur and business advisor with over 30 years of experience, specialising in data science, AI, and medical informatics. As the founder and CEO of Volv Global SA, he leads the company’s mission to transform healthcare through advanced machine learning methodologies, enabling early disease detection and precision medicine. His career includes designing global-scale data solutions for leading pharmaceutical companies, such as optimising a UK pharma’s operating model to reduce inventory by $750 million and establishing a €500 million drug pipeline budget management system for a European vaccines company. A recognised expert in life sciences data strategy, Christopher has been awarded for his contributions, including the CSC Ingenious Mind accolade with Dr Robert Wah. He also shares his expertise as a visiting professor at EPFL and UNIL, guiding executive management on harnessing data for strategic decision-making. Residing in Lausanne, Switzerland, he balances his professional pursuits with a passion for music, skiing, hiking, and cooking.

 

Make your voice heard. Be part of the solutions. Walk away with reliable, actionable steps. Volv Global has a small number of VIP tickets – if you would like to meet at the Rare Trials Summit, please Contact Us to book a meeting!

Looking forward to having great discussions with you there!